Welcome to our dedicated page for NewAmsterdam Pharma Co N.V. SEC filings (Ticker: NAMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewAmsterdam Pharma Co N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewAmsterdam Pharma Co N.V.'s regulatory disclosures and financial reporting.
James N. Topper, a director of NewAmsterdam Pharma Co N.V. (ticker: NAMSW), reported a purchase on Form 4. The filing shows a transaction on 09/15/2025 acquiring 660 ordinary shares at a weighted average price of $23.6953. The filing lists two holdings following the reported transaction: 3,028,524 shares held indirectly by Frazier Life Sciences X, L.P. and 3,801,000 shares held indirectly by Frazier Lifesciences Sponsor LLC. Footnotes state the reported price is a weighted average from multiple purchases priced between $23.46 and $23.75. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Topper on 09/17/2025.